Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Dermata Therapeutics, Inc.

Accession: 0001493152-26-012991

Filed: 2026-03-26

Period: 2026-03-26

CIK: 0001853816

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001853816

0001853816

2026-03-26

2026-03-26

0001853816

DRMA:CommonStockParValue0.0001PerShareMember

2026-03-26

2026-03-26

0001853816

DRMA:WarrantsExercisableForOneShareOfCommonStockMember

2026-03-26

2026-03-26

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): March 26, 2026

DERMATA

THERAPEUTICS, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-40739

86-3218736

(State

or other jurisdiction

(Commission

(IRS

Employer

of

incorporation)

File

Number)

Identification

No.)

3525

Del Mar Heights Rd., #322

San

Diego, CA

92130

(Address

of principal executive offices)

(Zip

Code)

(858)

800-2543

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of exchange on which registered

Common

Stock, par value $0.0001 per share

DRMA

The

Nasdaq Capital Market

Warrants,

exercisable for one share of Common Stock

DRMAW

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☒

If

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item

2.02. Results of Operation and Financial Condition.

On

March 26, 2025, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding

its results of operations for the fiscal year ended December 31, 2025. A copy of the press release is furnished under Item 2.02 as Exhibit

99.1.

The

information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed”

for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange

Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange

Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference

into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such

filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated March 26, 2026, issued by Dermata Therapeutics, Inc. entitled “Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025”

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

-2-

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

DERMATA

THERAPEUTICS, INC.

Dated:

March 26, 2026

By:

/s/

Gerald T. Proehl

Name:

Gerald

T. Proehl

Title:

President,

Chairman and Chief Executive Officer

-3-

EX-99.1

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Dermata

Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

-

Dermata announced a strategic pivot to develop and commercialize direct-to-consumer (“DTC”) skincare products under the

brand name Tome -

-

Dermata plans to launch its first DTC product, our Foundational Treatment, a once-weekly mask to support a skin renewal, in the middle

of 2026 -

-

Raised $4.125 million in gross proceeds from a private placement financing in December 2025, including participation from Dermata’s

Chief Executive Officer, Chief Financial Officer, and a member of the Company’s management -

SAN

DIEGO, CA, March 26, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata,” or the “Company”),

a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the

year ended December 31, 2025.

“We

are extremely excited as we approach the planned launch of our first DTC product in the middle of 2026, as this will be an important

milestone in our company’s evolution,” said Gerry Proehl, Chairman, President, and CEO of Dermata. “Our team has been

extremely busy over the past few months since we announced in September 2025 our strategic pivot to sell direct-to-consumer skincare

products. Since the announcement, we have recently revealed our new skincare brand, Tome, hired a new Vice President of Marketing to

lead the brand, and are close to finalizing the commercial packaging for our first product,” Mr. Proehl continued. “We believe

we can leverage our deep knowledge from years of clinical dermatology to deliver DTC skincare products that are efficacious and accessible

to consumers. With the cash raised from our recent financings, we believe we are in a good financial position for our planned product

launches, with potential revenue to follow,” concluded Mr. Proehl.

Kyra

Peckaitis, Dermata’s new Vice President of Marketing, commented, “Having recently joined Dermata, I’ve been incredibly

energized by both the strength of the team and opportunity to create something truly differentiated in the skincare market. We are very

excited to announce our first product by Tome, our Foundational Treatment, a once-weekly, foundational step designed to renew the appearance

of the skin and improve tone and texture over time. Our Foundational Treatment will incorporate our hero ingredient, Spongilla lacustris,

a wildly harvested freshwater sponge that we call Bioneedle, to provide consumers with the feel of an aesthetician treatment at home.”

Ms. Peckaitis continued, “We decided to fast-track the launch of the Foundational Treatment as we see this product reaching a larger

market, which can be used as the base product for any skincare routine. We continue to diligently work on our second product, our Clearing

Treatment for acne, which we expect to launch for the sizable acne market shortly after launching our Foundational Treatment. In a crowded

skincare landscape, we see a real opportunity to stand out by offering solutions that simplify routines while delivering meaningful improvements

in how consumer’s skin looks and feels, and we believe our Foundational Treatment and Clearing Treatment will do just that.”

Corporate

Highlights

●

Announced

strategic pivot to DTC skincare company. In September 2025, Dermata announced that it was making a strategic shift from developing

prescription dermatology products to developing and commercializing DTC skincare products. The Company is currently working on branding,

packaging, and manufacturing to prepare for the expected launch of its first DTC product, a once-weekly, foundational routine to

support skin renewal in the middle of 2026. The Company plans to sell multiple skincare products directly to consumers and directly

to aestheticians and dermatologists for in-office treatments.

●

Announced

the launch of its new skincare brand, Tome. In March 2026, Dermata revealed its new skincare brand, Tome, which aims to introduce

“skintech” at home. The Tome skincare line will emphasize products Dermata believes

can become the essential foundation of any well-rounded skincare routine. The Company plans to add multiple products to their Tome

skincare portfolio that utilize time-tested remedies to simplify skincare routines.

●

Announced

the hiring of Kyra Peckaitis as Vice President of Marketing. In March 2026, Ms. Peckaitis joined the Dermata team to lead the

launch of its new Tome skincare brand. Prior to joining Dermata, Ms. Peckaitis worked at Coterie helping to build its DTC baby care

brand. Ms. Peckaitis brings years of experience in DTC marketing and brand building.

●

Raised

$15.4 million in gross proceeds during 2025 and beginning of 2026. The funds raised during 2025, along with the proceeds from

the Company’s at-the-market facility in January 2026, are expected to fund its operations into the first quarter of 2027.

●

Announced

positive topline data from its XYNGARI Phase 3 STAR-1 clinical trial in moderate-to-severe acne. In March 2025, Dermata announced

that its STAR-1 study met all three primary endpoints by producing highly statistically significant results versus placebo at the

end of study. In April 2025, Dermata also announced that XYNGARI achieved statistically significant separation from placebo after

just 4 weeks, or only four treatments. The STAR-1 study tested Spongilla lacustris as a treatment for moderate-to-severe acne,

adding to the prior Phase 2b study where XYNGARI achieved statistically significant separation from placebo at all time points. However,

the Company has since withdrawn the investigational new drug application for XYNGARI to pursue its new commercial strategy of selling

DTC skincare products.

Anticipated

Upcoming Milestones

●

Launch

first DTC product, Foundational Treatment, in the middle of 2026. The Company is close to finalizing packaging for the upcoming

launch of its Foundational Treatment. The Company believes the Foundational Treatment can be the base of any skincare routine, designed

to renew the appearance of the skin and simplify skincare with a once-weekly application. The Company anticipates being ready to

launch the Foundational Treatment in the middle of 2026.

●

Launch

second DTC product, Clearing Treatment, an over-the-counter (“OTC”) acne treatment. The Company is also working on

finalizing its second DTC product, its Clearing Treatment, targeting consumers suffering from common forms of acne. This OTC acne

treatment will incorporate an FDA approved OTC active ingredient along with the Company’s Bioneedle, to provide patients with

a targeted treatment for their acne. The Clearing Treatment is expected to launch shortly after the Foundational Treatment.

Year

Ended 2025 Financial Results

As

of December 31, 2025, the Company had $7.5 million in cash and cash equivalents, compared to $3.2 million as of December 31, 2024. The

$4.3 million increase in cash and cash equivalents for the year ended December 31, 2025, resulted from approximately $12.1 million of

net financing proceeds offset by $7.8 million of cash used in operations. The Company expects its current cash resources to be sufficient

to fund operations into the first quarter of 2027.

Research

and development expenses were $2.9 million for the year ended December 31, 2025, compared to $8.2 million for the year ended December

31, 2024. The $5.3 million decrease in research and development expenses was primarily the result of a $5.1 million of decrease in clinical

expenses from our STAR-1 acne study, which was completed during the second quarter of 2025. Other research and development activities,

including chemistry, manufacturing and controls, or CMC, and non-clinical expenses also decreased by $0.1 million from the prior year

as result of the Company’s pivot to focus on DTC product sales. The remaining decrease in research and development expenses of

$0.1 million was related to personnel expenses.

Selling,

general and administrative expenses increased by approximately $0.5 million from $4.3 million for the year ended December 31, 2024, to

$4.8 million for the year ended December 31, 2025. The increase in selling, general and administrative expenses was primarily attributable

to $0.7 million in marketing expenses incurred during the year ended December 31, 2025, offset by approximately $0.2 million in decreased

personnel expenses.

About

Dermata Therapeutics

Dermata

Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development

to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing

a first-of-its-kind skin refresh and acne treatments that incorporates Dermata’s Bioneedle. The Company plans to launch its initial

product in the middle of 2026 with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more

information, or to join our mailing list, please visit http://www.dermatarx.com/.

About

Tome Skincare

Tome

is Dermata’s new skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal

meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in

science and history. Tome will consist of a line of skincare products utilizing Spongilla lacustris, a wildly harvested, freshwater

sponge that has evolved over millions of years, for consumers that are compelled by history and science to find the most potent products

for their skincare routine. Dermata believes its Tome skincare line will simplify existing skincare routines with essential ingredients

that deliver results, without harmful extremes. Dermata expects to launch its first product in the middle of 2026 with additional product

launches planned to follow. Start your skincare story at www.tomeskincare.com.

Forward-Looking

Statements

Statements

in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company’s

current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown

risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata’s shift to

prioritize DTC skincare products; the anticipated benefits of Dermata’s strategic shift to prioritize DTC skincare products, including

acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the success,

cost, and timing of the launch of its planned or future DTC products, including Foundational Treatment; the expected timing and success

of any planned or future DTC product launches, including Clearing Treatment; expectations for the success of the Company’s products

and their ability to generate revenue for the Company; the Company’s expectations with regard to current cash and cash equivalents

and the amount of time it will fund operations; and other factors described in the Company’s filings with the Securities and Exchange

Commission. These forward-looking statements are generally identified by the use of such words as “may,” “could,”

“should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,”

“expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential”

and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and

expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in

any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization.

For a discussion of these and other factors, please refer to Dermata’s filings with the Securities and Exchange Commission. You

are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is

made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified

in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect

events or circumstances after the date hereof, except as required by law.

DERMATA

THERAPEUTICS, INC.

Balance

Sheets

December 31, 2025

December 31, 2024

In thousands USD

Assets

Cash and cash equivalents

$ 7,522

$ 3,162

Prepaid expenses and other current assets

342

372

Total assets

7,864

3,534

Liabilities

Accounts payable

461

808

Accrued liabilities

1,180

1,165

Total liabilities

1,641

1,973

Equity

6,223

1,561

Total liabilities and equity

$ 7,864

$ 3,534

DERMATA

THERAPEUTICS, INC.

Statements

of Operations

Year Ended December 31,

2025

2024

In thousands, except share and per share data

Operating expenses

Research and development (1)

$ 2,930

$ 8,204

Selling, general and administrative (1)

4,844

4,309

Total operating expenses

7,774

12,513

Loss from operations

(7,774 )

(12,513 )

Interest income, net

215

226

Net loss

$ (7,559 )

$ (12,287 )

Net loss per common share, basic and diluted

$ (8.16 )

$ (80.32 )

Weighted average common shares outstanding, basic and diluted

926,192

152,974

(1) Includes the following stock-based compensation expense

Research and development

$ 32

$ 251

Selling, general and administrative

$ 112

$ 406

Investors:

Cliff

Mastricola

Investor

Relations

cmastricola@dermatarx.com

GRAPHIC

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (4168 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Mar. 26, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 26, 2026

Entity File Number

001-40739

Entity Registrant Name

DERMATA

THERAPEUTICS, INC.

Entity Central Index Key

0001853816

Entity Tax Identification Number

86-3218736

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

3525

Del Mar Heights Rd.

Entity Address, Address Line Two

#322

Entity Address, City or Town

San

Diego

Entity Address, State or Province

CA

Entity Address, Postal Zip Code

92130

City Area Code

(858)

Local Phone Number

800-2543

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

true

Common Stock, par value $0.0001 per share

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

DRMA

Security Exchange Name

NASDAQ

Warrants, exercisable for one share of Common Stock

Title of 12(b) Security

Warrants,

exercisable for one share of Common Stock

Trading Symbol

DRMAW

Security Exchange Name

NASDAQ

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=DRMA_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=DRMA_WarrantsExercisableForOneShareOfCommonStockMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type: